The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents

Andreas M ReimoldDallas Veterans Affairs Medical Center and Rheumatic Diseases Division, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Reimold AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/cfc3051d236445f0af47fea6195a5b7a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cfc3051d236445f0af47fea6195a5b7a
record_format	dspace
spelling	oai:doaj.org-article:cfc3051d236445f0af47fea6195a5b7a2021-12-02T00:22:09ZThe role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents1179-156Xhttps://doaj.org/article/cfc3051d236445f0af47fea6195a5b7a2012-05-01T00:00:00Zhttp://www.dovepress.com/the-role-of-adalimumab-in-rheumatic-and-autoimmune-disorders-compariso-a9849https://doaj.org/toc/1179-156XAndreas M ReimoldDallas Veterans Affairs Medical Center and Rheumatic Diseases Division, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#39;s disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with ADA. Long-term extension studies of some of the initial clinical trials, as well as data from large patient registries, are demonstrating ongoing benefit for responders. Potential side effects such as increased risk of infection, lymphoma, congestive heart failure, and demyelination continue to be examined, as the available data are not unanimous in showing an increase in incidence. In balancing both the advantages and the disadvantages of using ADA, the drug&#39;s overall effectiveness and its availability for use in patients with hepatic or renal comorbidities are weighed against the high cost. ADA is expected to have a leading role in the treatment of rheumatoid arthritis and other inflammatory conditions for years to come. Future studies will need to address the optimal sequence of disease-modifying antirheumatic drugs and biologics to use, combinations of disease-modifying antirheumatic drugs and biologics, and head-to-head comparisons of biologics in clinical trials. For those who go into clinical remission on an anti-tumor necrosis factor medication, unanswered questions remain about identifying the patients who can maintain the remission off all drugs, or at least off injected medication. Given the cost of biologic drugs, even studies that increase the interval between drug doses in well-controlled patients could provide financial benefits.Keywords: rheumatoid arthritis, Humira&reg;, tumor necrosis factor alpha, disease-modifying antirheumatic drugReimold AMDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2012, Iss default, Pp 33-47 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Reimold AM The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
description	Andreas M ReimoldDallas Veterans Affairs Medical Center and Rheumatic Diseases Division, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#39;s disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with ADA. Long-term extension studies of some of the initial clinical trials, as well as data from large patient registries, are demonstrating ongoing benefit for responders. Potential side effects such as increased risk of infection, lymphoma, congestive heart failure, and demyelination continue to be examined, as the available data are not unanimous in showing an increase in incidence. In balancing both the advantages and the disadvantages of using ADA, the drug&#39;s overall effectiveness and its availability for use in patients with hepatic or renal comorbidities are weighed against the high cost. ADA is expected to have a leading role in the treatment of rheumatoid arthritis and other inflammatory conditions for years to come. Future studies will need to address the optimal sequence of disease-modifying antirheumatic drugs and biologics to use, combinations of disease-modifying antirheumatic drugs and biologics, and head-to-head comparisons of biologics in clinical trials. For those who go into clinical remission on an anti-tumor necrosis factor medication, unanswered questions remain about identifying the patients who can maintain the remission off all drugs, or at least off injected medication. Given the cost of biologic drugs, even studies that increase the interval between drug doses in well-controlled patients could provide financial benefits.Keywords: rheumatoid arthritis, Humira&reg;, tumor necrosis factor alpha, disease-modifying antirheumatic drug
format	article
author	Reimold AM
author_facet	Reimold AM
author_sort	Reimold AM
title	The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
title_short	The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
title_full	The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
title_fullStr	The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
title_full_unstemmed	The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
title_sort	role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/cfc3051d236445f0af47fea6195a5b7a
work_keys_str_mv	AT reimoldam theroleofadalimumabinrheumaticandautoimmunedisorderscomparisonwithotherbiologicagents AT reimoldam roleofadalimumabinrheumaticandautoimmunedisorderscomparisonwithotherbiologicagents
_version_	1718403829176729600

The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents

Ejemplares similares